share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Shanahan Karin

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities

施貴寶 | 4：持股變動聲明
SEC announcement ·  03/12 17:54
Moomoo AI 已提取核心訊息
Bristol-Myers Squibb EVP, Karin Shanahan, completed a transaction involving the company's common stock on March 10, 2024. The action involved direct and indirect holdings, with Shanahan now owning a total of 3,226 shares directly and 818.59 shares indirectly through the BMS Savings and Investment Program. The common stock is listed with a par value of $0.10. This transaction reflects changes in the executive's stake in the company, which is a key interest for investors monitoring insider activity.
Bristol-Myers Squibb EVP, Karin Shanahan, completed a transaction involving the company's common stock on March 10, 2024. The action involved direct and indirect holdings, with Shanahan now owning a total of 3,226 shares directly and 818.59 shares indirectly through the BMS Savings and Investment Program. The common stock is listed with a par value of $0.10. This transaction reflects changes in the executive's stake in the company, which is a key interest for investors monitoring insider activity.
百時美施貴寶執行副總裁卡琳·沙納漢於2024年3月10日完成了一項涉及該公司普通股的交易。該行動涉及直接和間接持有，沙納漢現在直接持有總計3,226股股票，通過BMS儲蓄和投資計劃間接擁有818.59股股票。普通股的面值爲0.10美元。該交易反映了該公司高管股份的變化，這是監督內部活動的投資者的主要利益。
百時美施貴寶執行副總裁卡琳·沙納漢於2024年3月10日完成了一項涉及該公司普通股的交易。該行動涉及直接和間接持有，沙納漢現在直接持有總計3,226股股票，通過BMS儲蓄和投資計劃間接擁有818.59股股票。普通股的面值爲0.10美元。該交易反映了該公司高管股份的變化，這是監督內部活動的投資者的主要利益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息